Jimandin

Sitagliptin, the active ingredient in Jimandin, is a DPP‑4 inhibitor presented as an oral dosage form for oral use. It treats type 2 diabetes mellitus in adult patients, helping to improve glycemic control when used with diet and exercise. GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus, acting on the incretin pathway to lower blood glucose. - Type 2 diabetes mellitus: improves glycemic control as monotherapy when diet and exercise are insufficient. - Combination therapy with metformin: provides additional HbA1c reduction in patients inadequately controlled on metformin alone. - Combination with insulin or sulfonylureas: helps achieve target glucose levels while allowing lower doses of insulin or sulfonylureas.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Upper respiratory tract infection: cough, sore throat, or congestion. - Nausea: occasional mild nausea. - Diarrhea: loose stools, usually self‑limiting. - Arthralgia: mild joint pain.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Joint swelling or pain: may indicate autoimmune reaction. - Hypoglycemia: especially when combined with insulin or sulfonylureas.

Before initiating therapy, consider the following precautions: - Renal function: adjust dose in patients with severe renal impairment. - Hepatic impairment: use with caution in moderate to severe liver disease. - History of pancreatitis: avoid use and monitor for symptoms. - Concomitant insulin or sulfonylureas: monitor blood glucose to prevent hypoglycemia. - Pregnancy and breastfeeding: limited data; use only if potential benefit justifies the risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Insulin: increased risk of hypoglycemia. - Sulfonylureas: heightened hypoglycemia potential. - Strong CYP3A4 inducers (e.g., rifampin): may reduce sitagliptin exposure. Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and potassium levels. - Diuretics: watch for electrolyte disturbances. - Warfarin: periodic INR monitoring recommended.